This study is for people with colorectal cancer (CRC) who have minimal residual disease (MRD), meaning a small amount of cancer cells remain after initial treatment. The goal is to see how well biomarker-directed therapies (treatments chosen based on specific features of your cancer, like BRAF or KRAS mutations) help clear these remaining cancer cells, as measured by circulating tumor DNA (ctDNA) in your blood. You would receive treatment decided by your doctor as part of your usual care. Researchers will monitor your progress and collect blood samples every three months to understand how these treatments affect your ctDNA and the chance of your cancer returning. To join, you must be over 18, have a confirmed diagnosis of colorectal adenocarcinoma, and have no clear signs of cancer on scans after initial treatment.

Study design

This is an observational study with 40 planned participants. It is not a randomized trial, meaning treatments are not assigned by the study.

What's involved

You will follow your doctor's treatment plan and provide blood samples every 3 months for correlative studies.

Compensation

Not stated in the trial record.

Follow-up

Your safety and side effects will be monitored through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.